HHLR ADVISORS, LTD.
13F Holdings and Portfolio Analysis
Zhang Lei 2022 Q1 13F holdings, quarterly changes, portfolio value trend and position weight distribution.
HHLR ADVISORS, LTD. Overview
HHLR ADVISORS, LTD. held 64 stocks in 2022 Q1, with total market value around $4.79B.
HHLR ADVISORS, LTD.'s top five holdings in 2022 Q1: BeOne Medicines AG(ONC) 21.55%, JD.com, Inc.(JD) 10.19%, DoorDash, Inc.(DASH) 9.50%, Salesforce, Inc.(CRM) 9.39%, Legend Biotech Corporation(LEGN) 5.26%.
- Portfolio Value
- $4.79B
- Current Holdings
- 64 stocks
- New / Increased
- 5 / 8
- Reduced / Exited
- 8 / 17
Current Holdings
| 1 | BeOne Medicines AGONC | 1.03 | 21.55% | 5.47 - | $188.60 | $316.42 +67.77% | $136.90 | 0.00 | 3.50 | +$0.98B+131.14% | Held |
| 2 | JD.com, Inc.JD | 0.49 | 10.19% | 8.43 +76.92% | $57.87 | $33.07 -42.85% | $58.67 | +3.67 | 3.50 | -$0.22B-43.64% | Increased |
| 3 | DoorDash, Inc.DASH | 0.45 | 9.50% | 3.88 +199.44% | $117.19 | $154.61 +31.93% | $47.95 | +2.59 | 1.50 | +$0.41B+222.47% | Increased |
| 4 | Salesforce, Inc.CRM | 0.45 | 9.39% | 2.12 +9.80% | $212.32 | $210.90 -0.67% | $214.82 | +0.19 | 2.25 | -$0.01B-1.82% | Increased |
| 5 | Legend Biotech CorporationLEGN | 0.25 | 5.26% | 6.94 -41.24% | $36.34 | $31.96 -12.05% | $49.87 | -4.87 | 2.00 | -$0.12B-35.91% | Reduced |
| 6 | On Holding AGONON | 0.23 | 4.90% | 9.30 -41.78% | $25.24 | $41.82 +65.69% | $30.13 | -6.67 | 0.75 | +$0.11B+38.80% | Reduced |
| 7 | Vipshop Holdings LimitedVIPS | 0.20 | 4.16% | 22.15 +147.11% | $9.00 | $14.22 +58.00% | $5.96 | +13.19 | 1.25 | +$0.18B+138.51% | Increased |
| 8 | iQIYI, Inc.IQ | 0.18 | 3.66% | 38.65 - | $4.54 | $2.03 -55.29% | $18.04 | 0.00 | 3.50 | -$0.62B-88.75% | Held |
| 9 | Sea LimitedSE | 0.17 | 3.63% | 1.45 +17.41% | $119.79 | $90.53 -24.43% | $85.63 | +0.22 | 0.75 | +$0.01B+5.72% | Increased |
| 10 | Mondelez International, Inc.MDLZ | 0.12 | 2.44% | 1.86 - | $62.78 | $62.41 -0.59% | $40.03 | 0.00 | 3.50 | +$0.04B+55.91% | Held |
| 11 | NOVABRIDGE BIOSCIENCESNBP | 0.12 | 2.44% | 7.18 - | $16.24 | - | $50.06 | 0.00 | 1.75 | -$0.24B-67.56% | Held |
| 12 | Cytek Biosciences, Inc.CTKB | 0.09 | 1.97% | 8.76 - | $10.78 | $3.95 -63.36% | $21.41 | 0.00 | 0.75 | -$0.15B-81.55% | Held |
| 13 | DIDI GLOBAL INCDIDIY | 0.09 | 1.92% | 36.83 | $2.50 | - | $2.50 | +36.83 | 0.25 | $0.00B0.00% | New |
| 14 | Li Auto Inc.LI | 0.06 | 1.35% | 2.50 -50.14% | $25.81 | $22.51 -12.79% | $30.85 | -2.51 | 0.75 | -$0.02B-27.03% | Reduced |
| 15 | Gossamer Bio, Inc.GOSS | 0.06 | 1.34% | 7.42 - | $8.68 | $2.19 -74.77% | $16.64 | 0.00 | 3.25 | -$0.11B-86.84% | Held |
| 16 | KE Holdings Inc.BEKE | 0.06 | 1.34% | 5.18 +3.40% | $12.37 | $18.29 +47.86% | $59.68 | +0.17 | 1.75 | -$0.21B-69.35% | Increased |
| 17 | FULL TRUCK ALLIANCE CO LTDYMM | 0.06 | 1.34% | 9.59 | $6.67 | - | $6.67 | +9.59 | 0.25 | $0.00B0.00% | New |
| 18 | Playtika Holding Corp.PLTK | 0.06 | 1.32% | 3.28 - | $19.33 | $3.52 -81.79% | $27.21 | 0.00 | 1.25 | -$0.08B-87.06% | Held |
| 19 | ENFUSION INCENFN | 0.06 | 1.32% | 4.98 - | $12.72 | - | $20.94 | 0.00 | 0.50 | -$0.04B-39.26% | Held |
| 20 | Coupang, Inc.CPNG | 0.06 | 1.24% | 3.35 +38.15% | $17.68 | $16.68 -5.66% | $18.67 | +0.93 | 0.75 | -$0.01B-10.66% | Increased |
| 21 | BridgeBio Pharma, Inc.BBIO | 0.05 | 1.14% | 5.36 - | $10.15 | $54.92 +441.09% | $20.26 | 0.00 | 3.00 | +$0.19B+171.13% | Held |
| 22 | Uber Technologies, Inc.UBER | 0.04 | 0.83% | 1.11 - | $35.68 | $73.03 +104.68% | $29.85 | 0.00 | 2.75 | +$0.05B+144.64% | Held |
| 23 | argenx SEARGX | 0.04 | 0.79% | 0.12 - | $315.31 | $843.66 +167.57% | $218.35 | 0.00 | 2.50 | +$0.08B+286.39% | Held |
| 24 | TAIWAN SEMICONDUCTOR MFG LTDTSM | 0.04 | 0.78% | 0.36 - | $104.26 | $439.48 +321.53% | $56.77 | 0.00 | 2.00 | +$0.14B+674.14% | Held |
| 25 | Kiniksa Pharmaceuticals International, plcKNSA | 0.03 | 0.61% | 2.92 - | $9.94 | $38.64 +288.73% | $23.60 | 0.00 | 3.50 | +$0.04B+63.70% | Held |
Showing 1-25 of 64
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis is an estimate and can differ materially from the actual cost, especially in edge cases.
Cost basis estimate: from the latest uninterrupted holding period, new or increased shares are added to the cost pool at the report price; reductions remove shares at the then-average cost. Example: buy 100 shares at $10 in Q1 and add 50 shares at $16 in Q2, estimated cost basis is (100 x 10 + 50 x 16) / 150 = $12 per share.
Return shows estimated dollar return on top and percentage return below. It uses current price when available, otherwise report price.
Exited Holdings
Stocks no longer disclosed in the current 13F portfolio for 2022 Q1.
| 1 | Erasca, Inc.ERAS | 4.72 | 0.50 | $21.22 | $15.58 | -$0.03B-26.58% |
| 2 | Affiliated Managers Group, Inc.AMG | 0.34 | 2.25 | $28.12 | $164.51 | +$0.05B+484.97% |
| 3 | Amazon.com, Inc.AMZN | 0.01 | 0.25 | $3334.33 | $3259.95 | -$0.00B-2.23% |
| 4 | XPeng Inc.XPEV | 0.67 | 1.00 | $48.22 | $27.59 | -$0.01B-42.78% |
| 5 | Soho House & Co Inc.SHCO | 2.01 | 0.50 | $12.44 | $12.78 | +$0.00B+2.73% |
| 6 | Airbnb, Inc.ABNB | 0.15 | 0.75 | $153.14 | $166.49 | +$0.00B+8.72% |
| 7 | KANZHUN LIMITEDBZ | 0.53 | 0.75 | $39.65 | $24.91 | -$0.01B-37.18% |
| 8 | REGENXBIO Inc.RGNX | 0.46 | 2.75 | $42.72 | $32.70 | -$0.00B-23.46% |
| 9 | PDD HOLDINGS INC COMMON STOCKPDD | 0.21 | 3.25 | $34.21 | $40.11 | +$0.00B+17.25% |
| 10 | NIO Inc.NIO | 0.35 | 1.00 | $51.09 | $31.68 | -$0.01B-38.00% |
| 11 | Immunocore Holdings PLCIMCR | 0.28 | 1.00 | $42.57 | $34.24 | -$0.00B-19.57% |
| 12 | RALLYBIO CORPRLYB | 0.90 | 0.50 | $17.58 | $9.54 | -$0.01B-45.74% |
| 13 | PROMETHEUS BIOSCIENCES INCRXDX | 0.20 | 1.00 | $18.26 | $39.54 | +$0.00B+116.54% |
| 14 | Design Therapeutics, Inc.DSGN | 0.28 | 1.00 | $29.90 | $21.41 | -$0.00B-28.40% |
| 15 | MOGU Inc.MOGU | 10.45 | 2.75 | $2.68 | $0.38 | -$0.02B-85.83% |
| 16 | Krispy Kreme, Inc.DNUT | 0.19 | 0.50 | $13.96 | $18.92 | +$0.00B+35.50% |
| 17 | COINBASE GLOBAL INCCUSIP 19260Q107 | 0.01 | 0.50 | $227.49 | $189.86 | -$0.00B-16.54% |
Showing 1-17 of 17
Exited holdings are stocks disclosed in the previous report period but no longer disclosed in the current 13F portfolio.
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis uses the same weighted cost-pool method as current holdings. Estimated exit price uses the current report period weighted report price when available, otherwise the previous report price; it does not represent the actual sale price.
Exit return shows estimated dollar return on top and percentage return below.
Portfolio Visuals
Track portfolio value, position weights and Top 10 history.